For patients with normal glucose-6-phosphate dehydrogenase activity in malaria-endemic areas where frequent relapsing strains of Plasmodium vivax are prevalent, a 7-day high-dose course of primaquine was noninferior to a 14-day course.
Eli Lilly was the only pharmaceutical company providing quinidine gluconate in the United States, but in November 2017 it stopped manufacturing the drug and the remaining supplies expired.
In patients with malaria who have normal levels of glucose-6-phosphate dehydrogenase, 7-day primaquine was well tolerated and noninferior to 14-day primaquine.
High-resolution maps of Plasmodium falciparum malaria informs where malaria elimination efforts should be strengthened by highlighting where burden remains high.
Significant changes may have occurred in France, in the population that developed malaria after travel in endemic areas, which implies that preventative strategies need to be adapted.
The Food and Drug Administration has granted an investigational treatment for severe malaria Breakthrough Therapy designation.
The vaccine, called Mosquirix, was approved by the European Medicines Agency in 2015
Frequently repeated mass administration of ivermectin during transmission season may reduce the incidence of uncomplicated malaria episodes in children living in endemic regions, according to study results published in the Lancet.1 Since 2017, when researchers at the World Health Organization suggested that the global fight against malaria had stalled,2 novel ways to prevent the transmission…
The drug artesunate will become the first-line treatment for severe malaira in the US.
An expert meeting convened at NIAID, NIH, in Rockville, Maryland, in 2016 to discuss the rationale and design of malaria vaccine trials in pregnant women.
